NSCLC I
NSCLC II
MCRC I
MCRC II
100
Where would you go in the app to address “There are no Avastin efficacy data in the adenocarcinoma population”?
E4599 Track > E4599 Histologies
100
Where would you go in the app to deliver the core message “In Study E4599, Avastin plus PC demonstrated clinically meaningful 1 and 2 year survival in 1L mNSNSCLC"?
E4599 Track > OS
100
Where would you go in the app to address “I am concerned about using Avastin in patients on FDAC”?
Subgroup Analysis Track > NCCN (resection) and Surgery Timeline
100
Where would you go in the app to deliver the core message “Avastin is the only biologic with OS in both 1L and 2L MCRC”?
Avastin Foundation Track > Significant OS in 1L & 2L
200
Where would you go in the app to address “The efficacy data with Alimta/carbo is similar to Avastin + PC (OS, PFS, ORR) and better tolerated”?
E4599 Track > OS > PFS, RR, DCR > Safety Profile
200
Where would you go in the app to deliver the core message “Avastin plus PC demonstrated a median PFS of 6.2 months, based on investigator assessment”?
E4599 Track > PFS, RR, DCR > E4599 at 15mg/kg
Or
Historical Perspective & Key Trials Track > E4599 at 15mg/kg
Or
Dose Track > E4599 at 15mg/kg
200
Where would you go in the app to address “Avastin is not an appropriate choice for patients with liver only mets”?
Subgroup Analysis Track > 2107 Subgroups
200
Where would you go in the app to deliver the core message “Avastin is the only biologic with efficacy in combination with 3 distinct IV 5 FU chemo backbones: ILF, FOLFOX, IV 5FU”?
Avastin Foundation Track > Efficacy with 3 Chemo
Or
First Line Efficacy Track > 1L OS > PFS > NO16966
300
Where would you go in the app to address ”I use Avastin in combination with Alimta/carbo followed by maintenance Alimta or Tarceva”?
Tx Algorithm Track > Tx Algorithm Duration > NCCN and PI Duration
300
Where would you go in the app to deliver the core message “In the absence of disease progression, 60% of patients receiving Avastin plus PC in Study E4599 completed 6 cycles of therapy”?
E4599 Track > PFS, RR
300
Where would you go in the app to address “I use Erbitux in patients whose tumors are KRAS WT because of its superior efficacy”?
First-Line Efficacy Track > KRAS Status and Efficacy
300
Where would you go in the app to deliver the core message “Avastin plus IV 5 FU based therapy provides consistent OS benefits across all patient subtypes (including KRAS)”?
First Line Efficacy Track > KRAS Status and Efficacy
400
Where would you go in the app to address “There are no data confirming the efficacy of Avastin in the maintenance setting”?
Duration Track > Duration >NCCN and PI Duration
Or
E4599 Track > Duration > Duration Track > NCCN and PI Duration
Or
Treatment Algorithm Track > NCCN and PI Duration > E4599 Track or Duration Track > Duration
400
Where would you go in the app to deliver the core message “Bevacizumab is the only FDA approved agent for 1L mNSNSCLC that has an NCCN category 1 recommendation for continuation maintenance”?
Duration Track > NCCN and PI Duration
Or
Tx Algorithm Track > NCCN and PI Duration
400
Where would you go in the app to address “Avastin adds no benefit over chemo alone”?
Avastin Foundation Track > Efficacy with 3 Chemo
Or
First-Line Efficacy Track > 1L OS
400
Where would you go in the app to deliver the core message “OS benefits were achieved when Avastin was administered until disease progression or unacceptable toxicity”?
KRAS QH OS and PFS bar charts in additional materials button (must be within CRC content)
M
e
n
u